[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582848":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":27,"studyPopulation":20,"armGroups":28,"interventions":45,"overallOfficials":59,"centralContacts":63,"locations":68,"responsibleParty":84,"collaborators":87,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":20,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":99,"minAge":100,"maxAge":20,"enrollmentInfo":101,"targetDuration":20,"studyType":104,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":71,"whyStopped":20,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Columbia University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":20},[9,13],{"measure":10,"description":11,"timeFrame":12},"Acceptability among Patients","Acceptability of the intervention will be assessed using the validated Acceptability of Intervention Measure (AIM). AIM is a 4-item scale where respondents rate each item using a 5-point ordinal scale that ranges from 1=\"completely disagree\" to 5=\"completely agree\". The AIM is scored by averaging responses across the 4 items. A higher average score indicates greater acceptability, which is a better outcome.","6 months",{"measure":14,"description":15,"timeFrame":12},"Feasibility among Patients","Feasibility of the intervention will be assessed using the validated Feasibility of Intervention Measure (FIM). FIM is a 4-item scale where respondents rate each item using a 5-point ordinal scale that ranges from 1=\"completely disagree\" to 5=\"completely agree\". The FIM is scored by averaging responses across the 4 items. A higher average score indicates greater feasibility, which is a better outcome.",[17],{"measure":18,"description":19,"timeFrame":12},"Adherence to TAIL-PrEP intervention","Adherence to the intervention will be assessed by calculating the proportion of intervention components completed out of components possible.",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NON_RANDOMIZED","SINGLE_GROUP","PREVENTION",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE","Oral PrEP is highly effective but underutilized, with only 25% of individuals eligible for PrEP in the US having a prescription. Recent approval of cabotegravir-LA (cab-LA), a long-acting injectable integrase inhibitor and the first long-acting injectable PrEP, and lenacapavir (LEN), a long-acting class capsid inhibitor presents an opportunity to increase uptake. However, the long and variable half-life of cab-LA across different individuals after discontinuation (called the \"tail\") poses an implementation challenge. During the tail, cabotegravir levels are sub-therapeutic but could select for integrase-inhibitor resistance if the patient were to acquire HIV. This concern about the tail presents a barrier to providers prescribing cab-LA, potentially limiting the contribution of cab-LA to achieving End the HIV Epidemic targets and PrEP uptake and HIV infection. Currently, to mitigate this risk, individuals are advised to use oral PrEP for up to and beyond 12 months after stopping cab-LA injections if they have an ongoing risk of becoming infected with HIV. However, a risk mitigation strategy that requires daily oral PrEP may not be feasible or acceptable to many patients who started injectable PrEP precisely because they were unable or unwilling to adhere to a daily medication. LEN does not pose the same issue with a drug tail during discontinuation, but patients discontinuing LEN may need guidance on how to switch to other HIV prevention strategies rather than discontinuing HIV prevention altogether. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.",[29,35,40],{"label":30,"type":31,"description":32,"interventionNames":33},"Discontinued cab-LA","EXPERIMENTAL","Patients who recently discontinued cab-LA who receive the TAIL-PrEP intervention for patients who discontinued cab-LA",[34],"Behavioral: TAIL-PrEP for patients discontinuing cab-LA",{"label":36,"type":31,"description":37,"interventionNames":38},"Considering discontinuing cab-LA","Patients who are considering discontinuing cab-LA who receive the TAIL-PrEP intervention for patients considering discontinuing cab-LA",[39],"Behavioral: TAIL-PrEP for patients considering discontinuing cab-LA",{"label":41,"type":31,"description":42,"interventionNames":43},"Considering discontinuing LEN","Patients who are considering discontinuing LEN who receive the TAIL-PrEP intervention for patients considering discontinuing LEN",[44],"Behavioral: TAIL-PrEP for patients considering discontinuing LEN",[46,51,55],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":20},"BEHAVIORAL","TAIL-PrEP for patients discontinuing cab-LA","The TAIL-PrEP intervention is comprised of two components: (1) monthly cab-LA monitoring with specimens self-collected by patient and mailed to a lab for processing; and (2) monthly HIV prevention coaching with personalized cab-LA feedback.",[30],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":20},"TAIL-PrEP for patients considering discontinuing cab-LA","The TAIL-PrEP intervention is comprised of a one-time HIV prevention coaching session to guide patients considering discontinuing cab-LA on their HIV prevention options.",[36],{"type":47,"name":56,"description":57,"armGroupLabels":58,"otherNames":20},"TAIL-PrEP for patients considering discontinuing LEN","The TAIL-PrEP intervention is comprised of a one-time HIV prevention coaching session to guide patients considering discontinuing LEN on their HIV prevention options.",[41],[60],{"name":61,"affiliation":5,"role":62},"Kathrine A Meyers, DrPH","PRINCIPAL_INVESTIGATOR",[64],{"name":61,"role":65,"phone":66,"phoneExt":20,"email":67},"CONTACT","212 304 6110","kam2157@cumc.columbia.edu",[69],{"facility":70,"status":71,"city":72,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"Columbia University Irving Medical Center \u002F NewYork-Presbyterian Hospital","RECRUITING","New York","10032","United States","US",{"type":77,"coordinates":78},"Point",[79,80],-74.00597,40.71427,{"lat":80,"lon":79},[83],{"name":61,"role":65,"phone":20,"phoneExt":20,"email":67},{"type":62,"investigatorFullName":85,"investigatorTitle":86,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Kathrine Meyers","Associate Professor of Bio-Behavioral Sciences",[88],{"name":89,"class":90},"National Institute of Mental Health (NIMH)","NIH","100582848","the-tail-prep-study-100582848",false,"NCT06868641","The TAIL-PrEP Study","The TAIL-PrEP Study: Acceptability and Feasibility of a Tailored Adherence Intervention for Safe Discontinuation of Long-acting PrEP","Inclusion criteria:\n\n* At least 18 years of age\n* HIV-negative (self-report)\n* Able to speak and read in English\n* Have access to an internet-connected device capable of running the online video conferencing platform\n* Have a private location at which to take online conference calls\n\nParticipants considering discontinuing cab-LA or LEN have the following additional inclusion criteria:\n\n\\- Considering discontinuing cab-LA or LEN\n\nParticipants discontinuing cab-LA have the following additional inclusion criteria:\n\n* Have discontinued cab-LA injections within the last three months\n* Not currently on cab-LA injections\n* Able to receive and send monthly packages\n* The study period will end for patient participants once the monthly blood draw result indicates that cab-LA levels are not detectable (estimated average of 6 months across all patients) or after 6 months of the study, whichever comes first. If at 6 months of study participation, cab-LA levels are still detectable and participants adhered to at least 50% of study activities (self-collecting and mailing monthly blood samples, completing monthly surveys, attending monthly coaching sessions), participants will be invited to participate in the study for an additional 6 months, for a total of up to 12 study visits.",true,"ALL","18 Years",{"count":102,"type":103},30,"ESTIMATED","INTERVENTIONAL",[106],"NA","The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acceptability and feasibility of the TAIL-PrEP intervention: for participants discontinuing cab-LA, this will consist of monthly cabotegravir drug level monitoring to provide personalized HIV prevention coaching, for participants considering discontinuing cab-LA or LEN, this will consist of a one-time personalized HIV prevention coaching session. In Aim 2, the study will refine the TAIL-PrEP intervention and implementation strategy based on findings from the pilot study.",[109],"HIV Infections",[111,112,113,114,115,116,117],"HIV Prevention","PrEP","Cabotegravir","Long-Acting Injectable","Acceptability","Feasibility","Lenacapavir","2026-09-16",{"date":120,"type":121},"2026-09-21","ACTUAL",{"date":123,"type":121},"2026-06-03",{"date":125,"type":103},"2027-03",{"name":5,"class":6},1]